Litcius/Paper detail

Can PD-L1 expression be predicted by contrast-enhanced CT in patients with gastric adenocarcinoma? a preliminary retrospective study

Xiaolong Gu, Xianbo Yu, Gaofeng Shi, Yang Li, Yang Li

2022Abdominal Radiology11 citationsDOIOpen Access PDF

Abstract

BACKGROUND: This study aimed to construct a computed tomography (CT) radiomics model to predict programmed cell death-ligand 1 (PD-L1) expression in gastric adenocarcinoma patients using radiomics features. METHODS: A total of 169 patients with gastric adenocarcinoma were studied retrospectively and randomly divided into training and testing datasets. The clinical data of the patients were recorded. Radiomics features were extracted to construct a radiomics model. The random forest-based Boruta algorithm was used to screen the features of the training dataset. A receiver operating characteristic (ROC) curve was used to evaluate the predictive performance of the model. RESULTS: Four radiomics features were selected to construct a radiomics model. The radiomics signature showed good efficacy in predicting PD-L1 expression, with an area under the receiver operating characteristic curve (AUC) of 0.786 (p < 0.001), a sensitivity of 0.681, and a specificity of 0.826. The radiomics model achieved the greatest areas under the curve (AUCs) in the training dataset (AUC = 0.786) and testing dataset (AUC = 0.774). The calibration curves of the radiomics model showed great calibration performances outcomes in the training dataset and testing dataset. The net clinical benefit for the radiomics model was high. CONCLUSION: CT radiomics has important value in predicting the expression of PD-L1 in patients with gastric adenocarcinoma.

Topics & Concepts

RadiomicsReceiver operating characteristicMedicineAdenocarcinomaRetrospective cohort studyGastric adenocarcinomaHepatologyArea under the curveInternal medicineRadiologyCancerOncologyArtificial intelligenceComputer scienceRadiomics and Machine Learning in Medical ImagingCancer Immunotherapy and BiomarkersGastric Cancer Management and Outcomes